—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...

Show More From the Departments of Hematology/OncologyRadiation Therapy, Pathology and Laboratory Medicine, and Biostatistics, St Jude Children’s Research Hospital, and University of Tennessee at ...

With little data available on outcomes among patients who have B-cell lymphoma (BCL) and secondary central nervous system (CNS) involvement who were administered CD19-targeting chimeric antigen ...

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and aggressive form of non-Hodgkin lymphoma, with a standard treatment approach typically involving R-CHOP. Despite overall favourable ...

A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe ...

In our experience, patients' histories often note a neurologic prodrome years before PCNSL. These lingering illnesses, suggestive of multiple sclerosis or vitritis, might reflect polyclonal lymphoid ...

Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...

Please provide your email address to receive an email when new articles are posted on . SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or ...

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...